Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Hua CK, Ackerman ME.

Adv Drug Deliv Rev. 2016 Aug 1;103:157-73. doi: 10.1016/j.addr.2016.01.013. Epub 2016 Jan 29. Review.

2.

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.

3.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B.

PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.

4.

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.

Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR.

J Virol. 2015 Mar;89(5):2659-71. doi: 10.1128/JVI.03136-14. Epub 2014 Dec 17.

5.

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.

Zhang Z, Li S, Gu Y, Xia N.

Int J Mol Sci. 2016 Nov 18;17(11). pii: E1901. Review.

6.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

7.

Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System.

Bhiman JN, Lynch RM.

Curr HIV/AIDS Rep. 2017 Apr;14(2):54-62. doi: 10.1007/s11904-017-0352-1. Review.

8.

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Halper-Stromberg A, Nussenzweig MC.

J Clin Invest. 2016 Feb;126(2):415-23. doi: 10.1172/JCI80561. Epub 2016 Jan 11. Review.

9.
10.

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.

Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J; NISC Comparative Sequencing Program, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ.

J Virol. 2014 Nov;88(21):12669-82. doi: 10.1128/JVI.02213-14. Epub 2014 Aug 20.

11.

Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Ferreira CB, Merino-Mansilla A, Llano A, Pérez I, Crespo I, Llinas L, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

J Virol. 2013 Nov;87(22):12227-36. doi: 10.1128/JVI.02155-13. Epub 2013 Sep 4.

12.

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT.

J Virol. 2016 Jun 10;90(13):6127-6139. doi: 10.1128/JVI.00347-16. Print 2016 Jul 1.

13.

HIV broadly neutralizing antibody targets.

Wibmer CK, Moore PL, Morris L.

Curr Opin HIV AIDS. 2015 May;10(3):135-43. doi: 10.1097/COH.0000000000000153. Review.

14.

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL.

PLoS Pathog. 2013 Oct;9(10):e1003738. doi: 10.1371/journal.ppat.1003738. Epub 2013 Oct 31.

15.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8. Erratum in: Nature. 2016 Jul 28;535(7613):580.

16.

Antibody-Based Preventive and Therapeutic Strategies Against HIV.

Fabra-Garcia A, Beltran C, Sanchez-Merino V, Yuste E.

Curr HIV Res. 2016;14(3):260-9. Review.

PMID:
26957200
17.

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.

Asokan M, Rudicell RS, Louder M, McKee K, O'Dell S, Stewart-Jones G, Wang K, Xu L, Chen X, Choe M, Chuang G, Georgiev IS, Joyce MG, Kirys T, Ko S, Pegu A, Shi W, Todd JP, Yang Z, Bailer RT, Rao S, Kwong PD, Nabel GJ, Mascola JR.

J Virol. 2015 Dec;89(24):12501-12. doi: 10.1128/JVI.02097-15. Epub 2015 Oct 7.

18.

Anti-retroviral antibody FcγR-mediated effector functions.

Bournazos S, Ravetch JV.

Immunol Rev. 2017 Jan;275(1):285-295. doi: 10.1111/imr.12482. Review.

PMID:
28133801
19.

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.

Sun Z, Yan L, Tang J, Qian Q, Lenberg J, Zhu D, Liu W, Wu K, Wang Y, Lu S.

Virus Res. 2018 Jan 2;243:75-82. doi: 10.1016/j.virusres.2017.10.011. Epub 2017 Oct 16. Review.

PMID:
29051051
20.

Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.

Ahmad M, Ahmed OM, Schnepp B, Johnson PR.

Annu Rev Virol. 2017 Sep 29;4(1):491-510. doi: 10.1146/annurev-virology-101416-041929. Epub 2017 Jun 23. Review.

PMID:
28645240

Supplemental Content

Support Center